Abteilung für Herzchirurgie, Herzzentrum Universität Leipzig.
Dtsch Arztebl Int. 2011 Dec;108(48):816-21. doi: 10.3238/arztebl.2011.0816. Epub 2011 Dec 2.
Mitral valve regurgitation is the second most common clinically relevant valvular heart disease in adults, with an incidence of about 2% to 3% per year. Surgical mitral valve repair is the treatment of choice. Recent years have seen major advances in minimally invasive mitral valve surgery. Several new catheter-based techniques are now being clinically evaluated, including percutaneous endovascular mitral valve repair with a mitral clip.
This review is based on a selective review of the literature and on the authors' clinical experience.
Minimally invasive and reconstructive techniques for mitral valve surgery have come into more common use in recent years. In Germany, more than 50% of all mitral valve defects are now treated with a valve-preserving repair procedure. At the same time, percutaneous techniques have been developed that enable reduction of mitral regurgitation in the cardiac catheterization laboratory, without surgery. The implantation of a mitral clip is the sole currently approved technique of this type. In a recently published, randomized comparative clinical trial (EVEREST II), it was found to be safer, but less effective, than surgery.
Mitral valve surgery remains the treatment of choice for severe mitral regurgitation. For patients at high risk from surgery, and particularly those with severe heart failure, the implantation of a mitral clip is a safe and feasible treatment option.
二尖瓣反流是成人中第二常见的具有临床相关性的瓣膜性心脏病,其发病率约为每年 2%至 3%。手术二尖瓣修复是首选治疗方法。近年来,微创二尖瓣手术取得了重大进展。现在正在对几种新的基于导管的技术进行临床评估,包括使用二尖瓣夹进行经皮经血管二尖瓣修复。
本综述基于对文献的选择性回顾和作者的临床经验。
近年来,二尖瓣手术的微创和重建技术已得到更广泛的应用。在德国,现在超过 50%的二尖瓣缺陷采用保留瓣膜的修复手术进行治疗。与此同时,已经开发出了经导管技术,可在心导管实验室中减少二尖瓣反流,而无需手术。二尖瓣夹的植入是目前唯一获得批准的此类技术。在最近发表的一项随机对照临床试验(EVEREST II)中,发现该技术比手术更安全,但效果较差。
对于严重二尖瓣反流,二尖瓣手术仍然是首选治疗方法。对于手术风险高的患者,特别是那些患有严重心力衰竭的患者,二尖瓣夹的植入是一种安全且可行的治疗选择。